Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.

Abstract: The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising a chemopreventive agent disclosed herein.

Abstract: The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient in need thereof an antioxidant effective amount of a compound represented by formula I, IIa or IIb as disclosed herein.

Abstract: The present invention relates to a novel use of compounds having the general formula (I): CH3(—CH?CH)n—R??(I) where n=from 2 to 7, and R is chosen from among: CHO, CH2OH, CH2O—CO—R?, CO—OR?, CO—O(?), where R? is chosen from among H, the alkyl from C1 to C22, each compound of general formula (I) being used as such or in a mixture, as an active principle in a pharmaceutical or cosmetic composition to improve the human epidermal cell repair activity by means of the production of keratin mediated by the cytokeratins cK-19.

Abstract: The object of the present invention is the use of compounds designed to inhibit the activity of the enzyme 5?-reductase. This is a novel use of compounds of general formula (I): CH3(—CH?CH)n—R??(I) where n=from 2 to 7, and R is chosen from among: CHO, CH2OH, CH2O—CO—R?, CO—O(?), where R? is chosen from among H, and the alky from C1 to C22, each compound of general formula (I) being used as such or in mixtures with other compounds, as the active principle in a pharmaceutical or cosmetic composition designed to inhibit the action of the enzyme 5?-reductase, and of the pharmaceutical or cosmetic compositions deriving therefrom.

Abstract: This invention regards the use of zeaxanthin and/or rutin, as such or further combined with spermidine, as the active principle in a pharmaceutical, dietary, or cosmetic composition, acting to inhibit caspase-3 and therefore to control apoptosis by preventing programmed cell death. The indication for this composition according to the invention is primarily the treatment of scalp disorders characterized by excessive cellular turnover including chemotherapy-induced alopecia, alopecia areata, androgenetic alopecia and telogen effluvium.

Abstract: Rosiglitazone, 5-ASA or structurally analogous Compounds according to the general formula (I): or Compounds according to the general formula (Ia): For the induction of CAMP expression in tissues having PPAR-gamma receptors. Such tissues include epithelia or mucosae tissue having PPAR-gamma receptors and of particular interest is CAMP expression in the gut.

Abstract: There is a need for pharmaceutical compounds which have activity at, at least one of a PPAR and a cannabinoid receptor. Thus there are provided such compounds, wherein the compound comprises: a PPAR pharmacophore and a cannabinoid pharmacophore linked together by a moiety comprising a fused bicyclic ring comprising a five membered ring fused with a six membered ring or a six membered ring fused with a six membered ring; wherein the cannabinoid pharmacophore comprises the fused bicyclic ring; and the PPAR pharmacophore comprises a salicylic acid, alkoxybenzylacetic acid or a alkoxyphenylacetic acid functionality; and wherein the PPAR pharmacophore is linked to the bicyclic ring of the cannabinoid pharmacophore through a linker comprising an amine or an amide functional group.

Abstract: The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int)m-Ter, wherein m is between 0 and 12 and Int and Ter are Internal and Terminal building blocks, wherein Int is selected from the group consisting of formula (II); and Ter is selected from the group consisting of formula (III).

Abstract: In one aspect, the present invention relates to amino-salicylic-aminophenylpropionic compounds for the use in the treatment of the inflammatory component of the celiac disease. These compounds act by blocking the cytokines released in the celiac disease and are specifically useful in the treatment of cases refractory to the diet, in dietary errors and in the reduction of the celiac disease remission time.

Abstract: The present invention relates to the use of selected active principles of a natural origin in substitution of extract from Boehmeria Nipononivea for regulating the trophism of hair follicles and the production of sebum on the skin and its use in alopecia, with considerable practical advantages and with respect to the safety profile. The composition of the invention is based on an association of omega 6 polyunsaturated acids and rutin in a pharmaceutically acceptable carrier.

Abstract: The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int)m-Ter, wherein m is between 0 and 12 and Int and Ter are Internal and Terminal building blocks, wherein Int is selected from the group consisting of formula (II); and Ter is selected from the group consisting of formula (III).

Abstract: Therefore the present invention relates specifically to the compounds of general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising H, —CnH2n-1, a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R3 is selected from —CO—CH3, —NHOH, —OH, —OR6 in which R6 is a linear or branched alkyl group having from 1 to 6 carbon atoms; R4 is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, —CF3 or —CF2CF3, vinyl or allyl; R5, R7, R8 are hydrogen atoms; or R3 and R4, R4 and R5, or R7 and R8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.

Abstract: The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR3, —CH(OR3)COOH, in which R3 is selected from H, phenyl, benzyl, —CF3 or —CF2CF3, vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

Abstract: The invention concerns the use of spermine and spermidine as active ingredients in the preparation of a composition for dietary, pharmaceutical or cosmetic use in humans for health and beauty of the skin and skin appendages, and related compositions for pharmaceutical or dietary or cosmetic use for administration to humans.